B+
Bull case
20%
Probability
Target price
$270.00
+65.0% vs current
Market tone is cautiously constructive: the anchor price embeds some recovery but leaves room for upside if margins and buybacks accelerate. Near-term sentiment will pivot on earnings and any reimbursement or regulatory headlines.
No evidence quality warning is currently attached to this memo.
Quarterly results and guidance will test margin recovery; beats should re-rate shares, misses could trigger a pullback.
Adverse reimbursement or regulatory changes could compress margins and free cash flow, creating downside volatility.
Debt reduction or share repurchases would support EPS and multiple expansion over the next 6–18 months.
No formal recommendation provided.